# A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

> **NCT06741397** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ViiV Healthcare** · enrollment: 229 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** CAB LA
- **DRUG:** New formulation of CAB LA

## Key facts

- **NCT ID:** NCT06741397
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-20
- **Primary completion:** 2026-09-09
- **Final completion:** 2029-01-10
- **Target enrollment:** 229 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06741397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06741397, "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06741397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*